

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/963,827	09/26/2001	Bruce A. Sullenger	180/124/2	1175
25297	7590 06/23/2006		EXAMINER	
JENKINS, WILSON, TAYLOR & HUNT, P. A.			MCGARRY, SEAN	
3100 TOWER SUITE 1200	BLVD		ART UNIT	PAPER NUMBER
DURHAM, NC 27707			1635	
			DATE MAILED: 06/23/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

Application/Control Number: 09/963,827

Art Unit: 1635

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicants response to the Official Action mailed 9/30/05 is noted. It has come to the attention of the examiner that the application fails to comply with the sequence rules and compliance is required in order to fully consider applicant arguments filed in response to the above Official Action. Figure 18. both the originally filed Drawing and the new Drawing filed with the response to the above Official Action, contains sequences that do not have a corresponding Sequence Identifier. The application fails to comply with at least 37 C.F.R. 1.181(d). It is noted that the "Brief Description of the Drawings" section of the instant application also does not provide sequence identifiers for the sequences in Figure 18. It is also noted that the description of Figure 18 refers to Figure 1 where there are similar designation for the sequences present in the Figures. For example there are "9.3", "9.20", "9.25", etc designations in Figure 1 and "9-3", "9-20", "9-25", etc designations in Figure 18. It does not appear that the sequences for these designations correspond from Figure 1 to Figure 18. The examiner has not made a thorough review of the application for sequence compliance and applicant should make such a review to ensure sequence compliance. But it is also noted that Figure 30 contains a sequence that does not appear to have the required sequence identifier.

Application/Control Number: 09/963,827

Art Unit: 1635

Page 3

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean R. McGarry whose telephone number is (571) 272-0761. The examiner can normally be reached on M-Th (6:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/963,827

Art Unit: 1635

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Sean R McGarry Primary Examiner Art Unit 1635 Page 4

Application No.: 09/963,827

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. ∋ 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

x	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicants attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).			
	2. This application does not contain, as a separate part of the disclosure on paper copy, a Sequence Listing as required by 37 C.F.R. 1.821(c).			
	3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).			
	4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up Raw Sequence Listing.			
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).			
	6. The paper copy of the Sequence Listing is not the same as the computer readable from of the Sequence Listing as required by 37 C.F.R. 1.821(e).			
X	7. Other: See attached			
Applicant Must Provide:				
x	An initial or <u>substitute</u> computer readable form (CRF) copy of the Sequence Listing. (If the unidentified sequences are not provided on the CRF)			
X	An initial or <u>substitute</u> paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification. (If the unidentified sequences are not provided in the paper copy)			
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). (If a new paper and/or CRF are required)			
For	questions regarding compliance to these requirements, please contact:			
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 tentIn Software Program Support Technical Assistance703-287-0200			
	To Purchase Patentin Software703-306-2600			

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY